Key Takeaways
- Teva is seeking US Supreme Court review of its inhaler patent case after losing at the US Court of Appeals.
- The company was appealing a district court ruling ordering the company to delist five patents covering its ProAIR HFA inhaler from the Orange Book.
- Absent changes in the law, if the appeals court decision stands, companies could be voluntarily delisting patents from the Orange Book.
After another loss in the US Court of Appeals, Teva will seek a certiorari review by the US Supreme Court of its long-running inhaler patent...
Teva had requested a full panel rehearing in late 2024 after the appellate court affirmed a lower district court decision ordering the company to delist five patents covering its ProAir...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?